Steven Robert Pacelli net worth and biography

Steven Pacelli Biography and Net Worth

Insider of DexCom

Steve Pacelli is Executive Vice President and Managing Director, Dexcom Ventures.

In this role, Steve is focused on investment opportunities in sensing technology, data analytics, remote patient monitoring and population health, broadening Dexcom’s commitment to advancing better outcomes in healthcare.

Prior to this role, Steve was Executive Vice President of Strategy and Corporate Development from 2012 to 2021. Since joining Dexcom in April 2006, Steve has served in roles of increasing responsibility, including Chief Operating Officer, Chief Administrative Officer, Senior Vice President of Corporate Affairs and Vice President of Legal Affairs.

Prior to Dexcom, Steve served as a corporate attorney specializing in finance, mergers and acquisitions, and general corporate matters, and in an executive role as general counsel of several privately held companies.

Steve currently serves as a member of the Board of Directors of Biocom California, the largest and most experienced leader and advocate for California’s life science sector. He also serves as a member of the Board of Directors of Connect, a community nonprofit supporting innovators and entrepreneurs in Southern California by providing access to investors, mentors, and education, and as a member of the Board of Directors of EvoNexus, California’s leading non-profit startup technology incubator.

Steve is also a dedicated philanthropist, choosing to focus his efforts as a member of the Board of Directors of Big Brothers Big Sisters of San Diego, an organization dedicated to creating and supporting one-to-one mentoring relationships that ignite the power and promise of youth. He also serves as a member of the Board of Trustees of Pacific Ridge School, a group of dedicated and informed community leaders who are passionate about the value of education and are committed to building and strengthening the school.

Steve earned a Bachelor of Arts from the University of California, Los Angeles, and a JD from the University of Virginia. He is a member of the State Bar of California.

What is Steven Robert Pacelli's net worth?: The estimated net worth of Steven Robert Pacelli is at least $8.58 million as of November 24th, 2023. Mr. Pacelli owns 124,775 shares of DexCom stock worth more than $8,575,786 as of April 17th. This net worth evaluation does not reflect any other investments that Mr. Pacelli may own. Learn More about Steven Robert Pacelli's net worth.
How do I contact Steven Robert Pacelli?: The corporate mailing address for Mr. Pacelli and other DexCom executives is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. DexCom can also be reached via phone at (858) 200-0200 and via email at investorrelations@dexcom.com. Learn More on Steven Robert Pacelli's contact information.
Has Steven Robert Pacelli been buying or selling shares of DexCom?: Steven Robert Pacelli has not been actively trading shares of DexCom over the course of the past ninety days. Most recently, Steven Robert Pacelli sold 411 shares of the business's stock in a transaction on Friday, November 24th. The shares were sold at an average price of $110.80, for a transaction totalling $45,538.80. Following the completion of the sale, the director now directly owns 124,775 shares of the company's stock, valued at $13,825,070. Learn More on Steven Robert Pacelli's trading history.
Who are DexCom's active insiders?: DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (Executive Chairman, CEO & President), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?: During the last twelve months, insiders at the medical device company sold shares 18 times. They sold a total of 115,204 shares worth more than $8,969,704.72. The most recent insider tranaction occured on March, 17th when Director Bridgette P Heller sold 352 shares worth more than $24,756.16. Insiders at DexCom own 0.3% of the company. Learn More about insider trades at DexCom.
Information on this page was last updated on 3/17/2025.

Steven Robert Pacelli Insider Trading History at DexCom

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/24/2023	Sell	411	$110.80	$45,538.80	124,775
10/23/2023	Sell	411	$85.75	$35,243.25	125,186
9/22/2023	Sell	411	$88.40	$36,332.40	125,597
8/23/2023	Sell	411	$107.03	$43,989.33	126,008
7/24/2023	Sell	412	$130.58	$53,798.96	126,419
7/14/2023	Sell	5,031	$136.00	$684,216.00	126,831
6/23/2023	Sell	412	$125.92	$51,879.04	131,862
5/23/2023	Sell	412	$118.65	$48,883.80	132,274
4/27/2023	Sell	5,031	$126.00	$633,906.00	132,686
4/24/2023	Sell	412	$124.68	$51,368.16	137,717
3/23/2023	Sell	5,442	$116.40	$633,448.80	138,129
2/23/2023	Sell	412	$111.64	$45,995.68	136,464
1/23/2023	Sell	412	$107.86	$44,438.32	136,876
12/23/2022	Sell	412	$112.57	$46,378.84	137,288
8/23/2022	Sell	1,000	$84.21	$84,210.00	137,700
7/25/2022	Sell	1,000	$83.07	$83,070.00	138,700
6/23/2022	Sell	1,000	$72.55	$72,550.00	139,700
5/24/2022	Sell	250	$296.33	$74,082.50	35,175
4/25/2022	Sell	250	$439.94	$109,985.00	35,425
3/23/2022	Sell	250	$459.98	$114,995.00
2/23/2022	Sell	250	$394.33	$98,582.50
1/24/2022	Sell	250	$416.77	$104,192.50
12/23/2021	Sell	250	$573.91	$143,477.50
11/23/2021	Sell	250	$612.26	$153,065.00
10/22/2021	Sell	250	$570.00	$142,500.00
9/23/2021	Sell	6,743	$573.34	$3,866,031.62
8/23/2021	Sell	1,078	$516.40	$556,679.20
7/23/2021	Sell	1,079	$452.18	$487,902.22
6/23/2021	Sell	1,079	$426.92	$460,646.68
4/23/2021	Sell	1,079	$410.31	$442,724.49
3/23/2021	Sell	1,079	$360.49	$388,968.71
3/10/2021	Sell	5,566	$362.92	$2,020,012.72
2/23/2021	Sell	1,079	$406.98	$439,131.42	21,524
1/22/2021	Sell	1,079	$368.82	$397,956.78	21,524
12/23/2020	Sell	1,079	$359.85	$388,278.15	33,499
11/23/2020	Sell	1,079	$318.99	$344,190.21	33,499
10/23/2020	Sell	1,079	$403.18	$435,031.22
10/1/2020	Sell	2,200	$411.20	$904,640.00
9/25/2020	Sell	2,000	$400.07	$800,140.00
9/23/2020	Sell	1,079	$395.11	$426,323.69	46,812
9/9/2020	Sell	4,580	$398.30	$1,824,214.00
8/24/2020	Sell	1,531	$427.24	$654,104.44
7/23/2020	Sell	1,531	$427.31	$654,211.61	51,482
6/23/2020	Sell	1,531	$409.37	$626,745.47	51,482
5/22/2020	Sell	1,531	$396.74	$607,408.94	51,482
3/23/2020	Sell	1,531	$209.23	$320,331.13
12/23/2019	Sell	1,532	$213.17	$326,576.44	48,444
9/23/2019	Sell	1,532	$155.47	$238,180.04	66,821
6/24/2019	Sell	3,116	$149.65	$466,309.40
5/23/2019	Sell	3,597	$116.71	$419,805.87	72,570
4/23/2019	Sell	3,596	$116.61	$419,329.56
3/22/2019	Sell	3,596	$140.04	$503,583.84
2/22/2019	Sell	1,667	$144.67	$241,164.89
1/23/2019	Sell	3,114	$149.74	$466,290.36
12/21/2018	Sell	3,114	$109.41	$340,702.74
10/23/2018	Sell	3,114	$128.85	$401,238.90
9/24/2018	Sell	3,114	$141.25	$439,852.50
8/23/2018	Sell	3,114	$139.96	$435,835.44
7/25/2018	Sell	3,114	$101.91	$317,347.74
9/25/2017	Sell	1,450	$69.81	$101,224.50
7/24/2017	Sell	1,450	$69.47	$100,731.50
6/23/2017	Sell	1,450	$78.19	$113,375.50
10/24/2016	Sell	10,300	$81.95	$844,085.00
8/23/2016	Sell	10,300	$90.74	$934,622.00
6/23/2016	Sell	10,300	$77.40	$797,220.00
6/8/2016	Sell	18,239	$70.88	$1,292,780.32	182,518
4/27/2016	Sell	2,361	$70.39	$166,190.79	201,757
4/4/2016	Sell	20,600	$70.62	$1,454,772.00	204,118
1/25/2016	Sell	10,300	$73.24	$754,372.00	205,914
9/23/2015	Sell	14,000	$98.08	$1,373,120.00	216,214
8/28/2015	Sell	19,854	$94.67	$1,879,578.18	228,792
8/24/2015	Sell	14,000	$84.18	$1,178,520.00	248,646
6/23/2015	Sell	14,000	$77.53	$1,085,420.00
4/23/2015	Sell	39,709	$69.63	$2,764,937.67
3/23/2015	Sell	14,000	$61.33	$858,620.00
1/26/2015	Sell	24,532	$59.67	$1,463,824.44
1/13/2015	Sell	9,468	$62.22	$589,098.96
1/12/2015	Sell	20,000	$59.18	$1,183,600.00
12/23/2014	Sell	14,000	$54.62	$764,680.00
10/23/2014	Sell	14,000	$43.60	$610,400.00
9/23/2014	Sell	14,000	$40.32	$564,480.00
8/26/2014	Sell	30,000	$44.56	$1,336,800.00
8/25/2014	Sell	14,000	$44.24	$619,360.00
7/23/2014	Sell	14,000	$38.28	$535,920.00
6/23/2014	Sell	14,000	$41.02	$574,280.00
4/23/2014	Sell	14,000	$35.90	$502,600.00	241,399
3/24/2014	Sell	14,000	$42.92	$600,880.00	241,399
2/25/2014	Sell	33,368	$44.93	$1,499,224.24	195,865
1/23/2014	Sell	14,000	$36.49	$510,860.00	195,865
6/11/2013	Sell	5,000	$22.31	$111,550.00

See Full Table

Steven Robert Pacelli Buying and Selling Activity at DexCom

DexCom Company Overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Today's Range

Now: $68.73

$67.75

$69.69

50 Day Range

MA: $75.73

$59.83

$90.75

2 Week Range

Now: $68.73

$57.52

$139.24

Volume

4,273,078 shs

Average Volume

4,206,437 shs

Market Capitalization

$26.95 billion

P/E Ratio

48.06

Dividend Yield

N/A

Beta

1.5